232 related articles for article (PubMed ID: 27835905)
1. CXCR4 antagonists suppress small cell lung cancer progression.
Taromi S; Kayser G; Catusse J; von Elverfeldt D; Reichardt W; Braun F; Weber WA; Zeiser R; Burger M
Oncotarget; 2016 Dec; 7(51):85185-85195. PubMed ID: 27835905
[TBL] [Abstract][Full Text] [Related]
2. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
3. A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer.
Bertolini G; Cancila V; Milione M; Lo Russo G; Fortunato O; Zaffaroni N; Tortoreto M; Centonze G; Chiodoni C; Facchinetti F; Pollaci G; Taiè G; Giovinazzo F; Moro M; Camisaschi C; De Toma A; D'Alterio C; Pastorino U; Tripodo C; Scala S; Sozzi G; Roz L
Mol Ther; 2021 Oct; 29(10):2963-2978. PubMed ID: 34023505
[TBL] [Abstract][Full Text] [Related]
4. An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients.
Taromi S; Kayser G; von Elverfeldt D; Reichardt W; Braun F; Weber WA; Zeiser R; Burger M
Clin Exp Metastasis; 2016 Oct; 33(7):651-60. PubMed ID: 27380917
[TBL] [Abstract][Full Text] [Related]
5. Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016.
Otani Y; Kijima T; Kohmo S; Oishi S; Minami T; Nagatomo I; Takahashi R; Hirata H; Suzuki M; Inoue K; Takeda Y; Kida H; Tachibana I; Fujii N; Kumanogoh A
FEBS Lett; 2012 Oct; 586(20):3639-44. PubMed ID: 22992418
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 regulates growth of both primary and metastatic breast cancer.
Smith MC; Luker KE; Garbow JR; Prior JL; Jackson E; Piwnica-Worms D; Luker GD
Cancer Res; 2004 Dec; 64(23):8604-12. PubMed ID: 15574767
[TBL] [Abstract][Full Text] [Related]
7. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
8. PTEN loss activates a functional AKT/CXCR4 signaling axis to potentiate tumor growth and lung metastasis in human osteosarcoma cells.
Xi Y; Qi Z; Ma J; Chen Y
Clin Exp Metastasis; 2020 Feb; 37(1):173-185. PubMed ID: 31571016
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 chemokine receptor antagonists: perspectives in SCLC.
Burger JA; Stewart DJ
Expert Opin Investig Drugs; 2009 Apr; 18(4):481-90. PubMed ID: 19335276
[TBL] [Abstract][Full Text] [Related]
10. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
Benedicto A; Romayor I; Arteta B
Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche.
Kim M; Koh YJ; Kim KE; Koh BI; Nam DH; Alitalo K; Kim I; Koh GY
Cancer Res; 2010 Dec; 70(24):10411-21. PubMed ID: 21056990
[TBL] [Abstract][Full Text] [Related]
13. CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis.
Sun X; Charbonneau C; Wei L; Yang W; Chen Q; Terek RM
Mol Cancer Ther; 2013 Jul; 12(7):1163-70. PubMed ID: 23686836
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
Xiang J; Hurchla MA; Fontana F; Su X; Amend SR; Esser AK; Douglas GJ; Mudalagiriyappa C; Luker KE; Pluard T; Ademuyiwa FO; Romagnoli B; Tuffin G; Chevalier E; Luker GD; Bauer M; Zimmermann J; Aft RL; Dembowsky K; Weilbaecher KN
Mol Cancer Ther; 2015 Nov; 14(11):2473-85. PubMed ID: 26269605
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
Lefort S; Thuleau A; Kieffer Y; Sirven P; Bieche I; Marangoni E; Vincent-Salomon A; Mechta-Grigoriou F
Oncogene; 2017 Mar; 36(9):1211-1222. PubMed ID: 27669438
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract][Full Text] [Related]
17. HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer.
Muralidharan R; Panneerselvam J; Chen A; Zhao YD; Munshi A; Ramesh R
Cancer Gene Ther; 2015 Dec; 22(12):581-90. PubMed ID: 26494555
[TBL] [Abstract][Full Text] [Related]
18. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer.
Singh B; Cook KR; Martin C; Huang EH; Mosalpuria K; Krishnamurthy S; Cristofanilli M; Lucci A
Clin Exp Metastasis; 2010 Apr; 27(4):233-40. PubMed ID: 20229045
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
